ArticlePloS one2026
Identification of empagliflozin-related hub genes in atherosclerosis and their correlations with immune infiltration: Network pharmacology and bioinformatics analyses.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtherosclerosis (AS) is by far the most frequent underlying cause of atherosclerotic cardiovascular disease. Recently, sodium-glucose cotransporter 2 (SGLT2) inhibitors stand out for their anti-atherosclerotic effects. The present study was conducted to explore the potential genetic and molecular mechanisms of empagliflozin, a selective SGLT2 inhibitor, in preventing AS, and the correlation of empagliflozin-related hub genes with immune cells.
methodsIn our study, pharmacology platforms were accessed to identify the empagliflozin-related genes (ERGs). AS datasets GSE100927 and GSE43292 were downloaded from the public GEO database to identify AS-differentially expressed genes (AS-DEGs). Furthermore, the empagliflozin-related DEGs (ERDEGs) were obtained by intersecting AS-DEGs and ERGs. ERDEGs were further analyzed for Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. The protein-protein interaction (PPI) network was constructed to screen for hub genes, which were subjected to regulatory network construction, ROC curve plotting, as well as validation analysis, correlation and Friends analysis, and CIBERSORT and ssGSEA analysis.
resultsA total of 33 genes were identified as ERDEGs, among which the empagliflozin-related hub genes were identified to be IL1B, EGFR, ERBB2, JAK2, SYK, and LGALS3 in AS. Furthermore, in terms of the characteristics of immune cells, there were significant correlations between ERBB2 and CD8 + T cells, IL1B and resting mast cells, LGALS3 and eosinophils, as well as JAK2 and CD56dim NK.
conclusionOur network pharmacology and bioinformatics analyses provide a comprehensive understanding of the potential mechanisms of empagliflozin in AS at the genomic level, with the discovery of significant correlations between the screened hub genes and various immune cell subsets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.